To start your customized experience click the start button
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Feature Video
Dr Noopur Raje opens this program with a brief discussion on the basics of multiple myeloma. She describes what the disease is, highlights key risk factors, and explains how she helps educate her patients on their diagnosis. Cynthia Harrington discusses her role as a nurse practitioner when working with multiple myeloma patients and why a team-based approach between healthcare providers and the patient is important.
Christina Loguidice
Experts in multiple myeloma share the newest information on the goals of therapy in symptomatic disease, testing for minimal residual disease, the role of transplantation, and the use of maintenance therapy.
Katie Kosko
Acupuncture is a powerful resource that has been around for thousands of years. The traditional Chinese medicine is effective in treating chronic pain and headaches, and is now being used by many patients with cancer as a complementary therapy alongside medicinal treatment.
Brielle Urciuoli
For people with multiple myeloma, dollars spent on treatment are being stretched farther than they used to be, a recent study shows.
Mindy Waizer
David S. Siegel, M.D., Ph.D., chief of the division of Multiple Myeloma at the John Theurer Cancer Center, attributes some of the progress in myeloma treatment to patients and how they advocate for themselves.  
Jason M. Broderick
The Food and Drug Administration (FDA) recently released a statement providing data from the two phase 3 trials testing Keytruda (pembrolizumab) in patients with multiple myeloma. The trials were placed on clinical holds by the FDA in July, after concerns arose regarding the drug’s safety in this group of patients.
Ariela Katz
Selinexor (KPT-330), a small-molecule inhibitor with a novel mechanism of action, is being investigated in patients with multiple myeloma (MM) who have become refractory to the many new options that have been introduced in recent years for patients with the malignancy.
Gina Columbus
Peter Voorhees, M.D., discusses the advancements in multiple myeloma treatment, as well as where he hopes the field will go in coming years. 
Jason M. Broderick
The Food and Drug Administration (FDA) granted an approval to Darzalex (daratumumab) for use in combination with Pomalyst (pomalidomide) and dexamethasone for patients who have multiple myeloma who have two or more prior therapies, including a proteasome inhibitor and Revlimid (lenalidomide).
Jason Harris
Merck will be pausing two trials testing Keytruda in patients with multiple myeloma.
Jason Harris
Many patients with relapsed or refractory multiple myeloma saw clinical remission with CAR T-cell therapy.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable